The Senate Judiciary Committee convened a hearing to examine competition in the prescription drug market, focusing on ensuring affordable and accessible medications. The Committee scrutinized with experts and patient advocates the range of tools used by brand-name drug manufacturers to delay the entry of generic and biosimilar drugs, such as patent thickets, product hopping, and “pay-for-delay” settlements. Committee members debated… (Colocho, May 22, 2024) #Biosimilars, #Drug Pricing, #Food and Drug Administration, #Generic Drugs, #Pharmacy Benefit Managers, #Transparency